Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?

Parkinsonism and Related Disorders

Volumn 13, Issue SUPPL. 3, 2007, Pages

  Youdim, Moussa B H ^a   Geldenhuys, Werner J ^b   Van der Schyf, Cornelis J ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

A2A receptor antagonists; Adenosine; Dal mechanims; Iron chelation; Ladostigil; M30; Rasagiline

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 4 BENZYL 3 HYDROXY 4 AZAHEXACYCLO[5.4.1.0 2,6 .0 3,10 .0 5,9 .0 8,11]DODECANE; 8 (3 CHLOROSTYRYL)CAFFEINE; ADENOSINE A2A RECEPTOR ANTAGONIST; AMINE OXIDASE (FLAVIN CONTAINING); CALCIUM CHANNEL BLOCKING AGENT; CLIOQUINOL; DEFEROXAMINE; DIZOCILPINE; EPIGALLOCATECHIN GALLATE; HLA 20; IRON CHELATING AGENT; ISTRADEFYLLINE; LADOSTIGIL; LEVODOPA; MEMANTINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POLYPHENOL; RASAGILINE; RIVASTIGMINE; SCAVENGER; TV 1022; UNCLASSIFIED DRUG; VK 28;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; CALCIUM CHANNEL BLOCKERS; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; IRON CHELATING AGENTS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 38949111419     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(08)70017-8     Document Type: Article

References (115)

1. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3 (2002) 932-942
2. Lang A., and Lozano A. Parkinson's disease. Second of two parts. N Engl J Med 339 (1998) 1130-1143
3. Lang A., and Lozano A. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
4. Meissner W., Hill M., Tison F., Gross C., and Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25 (2004) 249-253
5. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., and Youdim M. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS drugs 17 (2003) 729-762
6. Schoenberg B. Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci 14 (1987) 407-413
7. Calne S., Schoenberg B., Martin W., Uitti R., Spencer P., and Calne D. Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 14 (1987) 303-305
8. Paolini M., Sapone A., and Gonzalez F. Parkinson's disease, pesticides and individual vulnerability. Trends Pharmacol Sci 25 (2004) 124-129
9. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
10. Schapira A., Bate G., and Kirkpatrick P. Rasagiline. Nat Rev 4 (2005) 625-626
11. Stocchi F., and Olanow C. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 53 Suppl 3 (2003) S87-S97 discussion: S97-8.
12. Hall E., Andrus P., Oostveen J., Althaus J., and VonVoigtlander P. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742 (1996) 80-88
13. Piercey M. Pharmacology of pramipexole, a dopamine D3- preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 21 (1998) 141-151
14. Dooley M., and Markham A. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging 12 (1998) 495-514
15. Plosker G., and Lyseng-Williamson K. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharm Econ 23 (2005) 193-206
16. Merello M., Nouzeilles M., Cammarota A., and Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double- blind crossover randomized study. Clin Neuropharmacol 22 (1999) 273-276
17. Rabey J., Nissipeanu P., and Korczyn A. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm 4 (1992) 277-282
18. Rogawski M., and Wenk G. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 9 (2003) 275-308
19. Zimmermann G., Lehar J., and Keith C. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12 (2007) 34-42
20. Morphy R., Kay C., and Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 9 (2004) 641-651
21. Morphy R., and Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48 (2005) 6523-6543
22. Gal S., Zheng H., Fridkin M., and Youdim M. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95 (2005) 79-88
23. Van der Schyf C., Gal S., Geldenhuys W., and Youdim M. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Invest Drugs 15 (2006) 873-886
24. Van der Schyf C., Geldenhuys W., and Youdim M. Multifunctional neuroprotective drugs for the treatment of cognitive and movement impaired disorders, including Alzheimer's and Parkinson's diseases. Drugs Future 31 (2006) 447-460
25. Youdim M., and Buccafusco J. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm 112 (2005) 519-537
26. Youdim M., and Buccafusco J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26 (2005) 27-35
27. Brooks D., Agid Y., Eggert K., Widner H., Ostergaard K., and Holopainen A. Treatment of end-of-dose wearing-off in parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 53 (2005) 197-202
28. Olanow C., Kieburtz K., Stern M., Watts R., Langston J., Guarnieri M., et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 61 (2004) 1563-1568
29. Wong D., Robertson D., Bymaster F., Krushinski J., and Reid L. LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci 43 (1988) 2049-2057
30. Kihara T., and Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272 (1995) 177-183
31. Goldstein D., Mallinckrodt C., Lu Y., and Demitrack M. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63 (2002) 225-231
32. Foley P., Gerlach M., Youdim M., and Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?. Parkinsonism Rel Disord 6 (2000) 25-47
33. Youdim M., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79 (2005) 172-179
34. Youdim M., Fridkin M., and Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mechanisms Ageing Dev 126 (2005) 317-326
35. Zheng H., Gal S., Weiner L., Bar-Am O., Warshawsky A., Fridkin M., et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95 (2005) 68-78
36. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., and Youdim M. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18 (2004) 1471-1473
37. Bar-Am O., Weinreb O., Amit T., and Youdim M. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19 (2005) 1899-1901
38. Youdim M., Gross A., and Finberg J. Rasagiline [N-propargyl-1R(+)aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132 (2001) 500-506
39. Rabey J., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23 (2000) 324-330
40. Stern M., Marek K., Friedman J., Hauser R., LeWitt P., Tarsy D., et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 19 (2004) 916-923
41. Thebault J., Guillaume M., and Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 24 (2004) 1295-1305
42. Heikkila R., Duvoisin R., Finberg J., and Youdim M. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 116 (1985) 313-317
43. Chen J., and Swope D. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45 (2005) 878-894
44. Chen J., and Ly A. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 63 (2006) 915-928
45. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
46. Bar-Am O., Amit T., and Youdim M. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 103 (2007) 962-971
47. Sterling J., Herzig Y., Goren T., Finkelstein N., Lerner D., Goldenberg W., et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45 (2002) 5260-5279
48. Weinstock M., Poltyrev T., Bejar C., and Youdim M. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 160 (2002) 318-324
49. Sagi Y., Weinstock M., and Youdim M. Attenuation of MPTP- induced dopaminergic neurotoxicity by TV3326, a cholinesterasemonoamine oxidase inhibitor. J Neurochem 86 (2003) 290-297
50. Youdim M., and Bakhle Y. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 Suppl 1 (2006) S287-S296
51. Magyar K., and Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25 (2004) 233-242
52. Youdim M. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and M30. Curr Alzheimer Res 3 (2006) 541-550
53. Magyar K., Palfi M., Tabi T., Kalasz H., Szende B., and Szoko E. Pharmacological aspects of (-)-deprenyl. Curr Med Chem 11 (2004) 2017-2031
54. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., and Yahr M. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106 (1984) 209-210
55. Wu W., Zhu X., Guan H., Wang R., and Ji X. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity. Zhongguo yao li xue bao [Acta Pharmacol Sinica] 20 (1999) 146-150
56. Koutsilieri E., Chen T., Rausch W., and Riederer P. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl- 4-phenylpyridinium. Eur J Pharmacol 306 (1996) 181-186
57. Fuller R., Hemrick-Luecke S., and Perry K. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Pharmacol Exp Ther 247 (1988) 531-535
58. Suuronen T., Kolehmainen P., and Salminen A. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 59 (2000) 1589-1595
59. Tatton W., Chalmers-Redman R., and Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110 (2003) 509-515
60. Tatton W., Wadia J., Ju W., Chalmers-Redman R., and Tatton N. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48 (1996) 45-59
61. De Colibus L., Li M., Binda C., Lustig A., Edmondson D., and Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 102 (2005) 12684-12689
62. Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M., et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113 (2006) 21-32
63. Maruyama W., Takahashi T., and Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70 (1998) 2510-2515
64. Zecca L., Youdim M., Riederer P., Connor J., and Crichton R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
65. Zheng H., Weiner L., Bar-Am O., Epsztejn S., Cabantchik Z., Warshawsky A., et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorganic Med Chem 13 (2005) 773-783
66. Shachar D., Kahana N., Kampel V., Warshawsky A., and Youdim M. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46 (2004) 254-263
67. Mandel S., Weinreb O., Amit T., and Youdim M. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res 48 (2005) 379-387
68. Avramovich-Tirosh Y., Amit T., Bar-Am O., Zheng H., Fridkin M., and Youdim M. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhbitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 100 (2007) 490-502
69. Weinreb O., Amit T., Bar-Am O., Chillag-Talmor O., and Youdim M. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann NY Acad Sci 1053 (2005) 348-355
70. Sagi Y., Mandel S., Amit T., and Youdim M. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25 (2007) 35-44
71. Zhu W., Xie W., Pan T., Xu P., Zheng H., Fridkin M., et al. Prevention and rescue of lactacystin induced nigrostriatal dopamine neurons degeneration by novel brain permeable iron chelators. FASEB J (2007) in press.
72. Riederer P., Danielczyk W., and Grunblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 25 (2004) 271-277
73. Saura J., Richards J., and Mahy N. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging 15 (1994) 399-408
74. Mahy N., Andres N., Andrade C., and Saura J. Age-related changes of MAO-A and -B distribution in human and mouse brain. Neurobiology (Budapest) 8 (2000) 47-54
75. Saura J., Andres N., Andrade C., Ojuel J., Eriksson K., and Mahy N. Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 18 (1997) 497-507
76. Sramek J., and Cutler N. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 14 (1999) 359-373
77. Maia L., and de Mendonca A. Does caffeine intake protect from Alzheimer's disease?. Eur J Neurol 9 (2002) 377-382
78. 2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138 (2003) 1207-1209
79. 2A receptors. Neurobiol Aging 26 (2005) 957-964
80. 2A receptor antagonists. Bioorganic Med Chem 11 (2003) 1299-1310
81. 2A receptor antagonism. J Biol Chem 277 (2002) 36040-36044
82. 2A receptor antagonists. Neurology 61 (2003) S62-S68
83. Horn J., and Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane database of systematic reviews (Online) (2000) CD001928
84. Kemp J., and McKernan R. NMDA receptor pathways as drug targets. Nature neuroscience 5 Suppl (2002) 1039-1042
85. Ovbiagele B., Kidwell C., Starkman S., and Saver J. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Cardiovasc Med 5 (2003) 441-449
86. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 79 (1999) 1431-1568
87. Gardoni F., and Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 545 (2006) 2-10
88. Zou J., and Crews F. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034 (2005) 11-24
89. Gerriets T., Stolz E., Walberer M., Kaps M., Bachmann G., and Fisher M. Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance. Stroke 34 (2003) 2234-2239
90. Green A., Odergren T., and Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents?. Trends Pharmacol Sci 24 (2003) 402-408
91. Gorgulu A., Kins T., Cobanoglu S., Unal F., Izgi N., Yanik B., et al. Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta neurochir 142 (2000) 1287-1292
92. Van der Schyf C., Squier G., and Coetzee W. Characterization of NGP1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol Res Commun 18 (1986) 407-417
93. Parsons C., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38 (1999) 735-767
94. Geldenhuys W., Malan S., Bloomquist J., and Van der Schyf C. Structure-activity relationships of pentacycloundecylamines at the N-methyl-D-aspartate receptor. Bioorganic Med Chem 15 (2007) 1525-1532
95. Kiewert C., Hartmann J., Stoll J., Thekkumkara T., Van der Schyf C., and Klein J. NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels. Neurochem Res 31 (2006) 395-399
96. Mdzinarishvili A., Geldenhuys W., Abbruscato T., Bickel U., Klein J., and Van der Schyf C. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci Lett 383 (2005) 49-53
97. Hansard M., Smith L., Jackson M., Cheetham S., and Jenner P. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol 451 (2002) 157-160
98. Kirby M., Barlow R., and Bloomquist J. Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes. Toxicol Appl Pharmacol 181 (2002) 89-92
99. Geldenhuys W., Malan S., Murugesan T., Van der Schyf C., and Bloomquist J. Synthesis and biological evaluation of pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease. Bioorganic Med Chem 12 (2004) 1799-1806
100. Geldenhuys W., Terre'Blanche G., Van der Schyf C., and Malan S. Screening of novel pentacyclo-undecylamines for neuroprotective activity. Eur J Pharmacol 458 (2003) 73-79
101. Weinreb O., Mandel S., Amit T., and Youdim M. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 15 (2004) 506-516
102. Hider R., Liu Z., and Khodr H. Metal chelation of polyphenols. Methods Enzymol 335 (2001) 190-203
103. Guo Q., Zhao B., Li M., Shen S., and Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys acta 1304 (1996) 210-222
104. Morel I., Lescoat G., Cogrel P., Sergent O., Pasdeloup N., Brissot P., et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol 45 (1993) 13-19
105. Joseph J., Shukitt-Hale B., and Casadesus G. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr 81 (2005) 313S-316S
106. Mandel S., Avramovich-Tirosh Y., Reznichenko L., Zheng H., Weinreb O., Amit T., et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neuro- Signals 14 (2005) 46-60
107. Mandel S., Amit T., Reznichenko L., Weinreb O., and Youdim M. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res 50 (2006) 229-234
108. Reznichenko L., Amit T., Youdim M., and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem 93 (2005) 1157-1167
109. Kumamoto M., Sonda T., Nagayama K., and Tabata M. Effects of pH and metal ions on antioxidative activities of catechins. Biosci Biotechnol Biochem 65 (2001) 126-132
110. Grinberg L., Newmark H., Kitrossky N., Rahamim E., Chevion M., and Rachmilewitz E. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol 54 (1997) 973-978
111. Levites Y., Amit T., Mandel S., and Youdim M. Neuroprotection and neurorescue against Ab toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 17 (2003) 952-954
112. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25 (2005) 8807-8814
113. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M., Weinreb O., et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 97 (2006) 527-536
114. Rogers J., and Lahiri D. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5 (2004) 535-551
115. Payton S., Cahill C., Randall J., Gullans S., and Rogers J. Drug discovery targeted to the Alzheimer's APP mRNA 5 -untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci 20 (2003) 267-275